Nuformix plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom. Show More...
-
Website https://www.nuformix.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.11 GBX
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-03 2011-03 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 TTM Earnings Per Share GBP -0.010 Dividends GBP Payout Ratio % * Shares Mil 96.0 374.0 461.0 464.0 Book Value Per Share * GBP 0.010 0.010 Free Cash Flow Per Share * GBP Return on Assets % -242.75 -72.85 -34.39 -23.63 Financial Leverage (Average) 1.12 1.21 1.14 Return on Equity % -424.52 -85.23 -39.99 -26.77 Return on Invested Capital % -424.52 -83.86 -39.19 -26.12 Interest Coverage -176.66 -63.87 -54.59 Current Ratio 0.1 1.34 0.42 0.47 Quick Ratio 0.1 0.92 0.19 0.47 Debt/Equity